Lupus drug hydroxychloroquine tested as COVID-19 shield
NCT ID NCT04481633
First seen Jan 04, 2026 · Last updated Jun 22, 2026 · Updated 24 times
Summary
This completed study looked at whether lupus patients already taking hydroxychloroquine long-term had a lower risk of catching COVID-19 or developing severe symptoms. Researchers compared 552 patients who either took the drug or did not, using blood tests and questionnaires. The goal was to see if the drug offered any real-world protection during the pandemic.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COVID-19 are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Haut-Lévêque Hospital - Gastro-entérologie
Pessac, 33604, France
-
Haut-Lévêque Hospital - Médecine interne
Pessac, 33604, France
-
Joseph Ducuing Hospital - Médecine interne
Toulouse, 31027, France
-
Limoges university Hospital
Limoges, 87042, France
-
Montpellier University Hospital
Montpellier, 31295, France
-
Pitié Salpêtrière Hospital - Hépatologie
Paris, 75651, France
-
Pitié Salpêtrière Hospital - Médecine interne
Paris, 75651, France
-
Toulouse University Hospital
Toulouse, 31059, France
-
Toulouse University Hospital - Rhumatologie
Toulouse, 31059, France
-
Toulouse university Hospital - Larrey Dermatologie
Toulouse, 31059, France
-
University Hospital of Toulouse - Rangueil Médecine interne
Toulouse, 31059, France
-
University hospital Toulouse - Purpan Médecine interne
Toulouse, 31059, France
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Hydroxychloroquine
What this could lead to
If it works, this could suggest that hydroxychloroquine helps protect people with autoimmune diseases from COVID-19 infection or severe illness.
What could go wrong
This is an observational study, not a controlled trial, so it cannot prove cause and effect. Results may not apply to the general population, and earlier studies on hydroxychloroquine for COVID-19 showed mixed or no benefit.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.